We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZTS icon
26
Zoetis
ZTS
$31.9B
$25.2M 0.95%
190,384
-58,640
-24% -$7.29M
SYK icon
27
Stryker
SYK
$133B
$23.9M 0.9%
113,667
-4,853
-4% -$1.01M
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.64B
$23.4M 0.89%
181,623
+41,344
+29% +$4.17M
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$11.7B
$23.4M 0.88%
276,560
+30,797
+13% +$2.33M
ISRG icon
30
Intuitive Surgical
ISRG
$126B
$22.9M 0.86%
116,049
-50,376
-30% -$9.43M
VTRS icon
31
Viatris
VTRS
$20.7B
$20.9M 0.79%
1,038,554
– –
NBIX icon
32
Neurocrine Biosciences
NBIX
$18.7B
$20.8M 0.78%
193,042
-13,780
-7% -$1.44M
HUM icon
33
Humana
HUM
$44B
$20.2M 0.76%
55,013
-29,221
-35% -$9.27M
NVS icon
34
Novartis
NVS
$301B
$20M 0.76%
211,047
-38,400
-15% -$3.45M
BDX icon
35
Becton Dickinson
BDX
$45.6B
$18M 0.68%
67,913
+8,014
+13% +$2M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$17M 0.64%
153,003
– –
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$27.4B
$16.6M 0.63%
143,795
-22,480
-14% -$2.24M
EW icon
38
Edwards Lifesciences
EW
$50B
$16.2M 0.61%
208,671
+12,951
+7% +$1.01M
WELL icon
39
Welltower
WELL
$170B
$15.7M 0.59%
191,646
+39,324
+26% +$3.37M
HCA icon
40
HCA Healthcare
HCA
$85.7B
$14.2M 0.54%
95,833
-2,560
-3% -$344K
AZN icon
41
AstraZeneca
AZN
$266B
$13.8M 0.52%
138,049
– –
ONC
42
BeOne Medicines Ltd
ONC
$33.4B
$13.4M 0.51%
81,089
-13,200
-14% -$2.19M
NVO
43
Novo Nordisk
NVO
$228B
$12.8M 0.48%
442,728
-39,272
-8% -$1.09M
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$16.2B
$12.8M 0.48%
85,673
+10,737
+14% +$1.46M
ESPR
45
DELISTED
Esperion Therapeutics
ESPR
$12.7M 0.48%
213,562
– –
IONS icon
46
Ionis Pharmaceuticals
IONS
$8.81B
$12.7M 0.48%
209,924
+23,680
+13% +$1.41M
GSK icon
47
GSK
GSK
$104B
$12.1M 0.46%
205,638
+20,232
+11% +$1.13M
OHI icon
48
Omega Healthcare
OHI
$15B
$12.1M 0.46%
284,795
+12,029
+4% +$509K
MIST icon
49
Milestone Pharmaceuticals
MIST
$143M
$12M 0.45%
746,653
+699,713
+1,491% +$12.4M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.7M 0.44%
147,168
+54,211
+58% +$3.21M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.